
Camlin Fine Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
Yes
Capex
Yes
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- Blends business expected to grow from Rs. 780 crores (FY24) to over Rs. 1,000 crores in FY25.
- Vanillin business projected to contribute around Rs. 200 crores in revenue in FY25.
- Hydroquinone and downstream products expected to add Rs. 600-700 crores revenue.
- Total conservative revenue outlook for FY25 is Rs. 1,800 - Rs. 1,900 crores, reflecting ~10% growth.
- Volume growth seen in TBHQ and BHA by 10-15% despite price reductions.
- North America and Brazil subsidiaries showing strong sales growth and positive EBITDA, likely to continue.
- Vanillin plant capacity utilization anticipated at 40-50% in FY25, ramping up sale and market share, including targeting 400-500 tons in India.
- Market demand expected to improve towards end of FY25 with possible price recovery.
- Repurposing of European and China plants planned to support future growth with CAPEX around $3 million each.
See what Camlin Fine management said on margin guidance — free account, 30 seconds.
Fundraise plans
NoSee what Camlin Fine management said on order book — free account, 30 seconds.
Capex plans
Yes- The Italy plant is being repurposed to produce MEHQ and Guaiacol, with financial closure pending; project stabilization and commercialization expected by end of FY25 (Page 13-14).
- Planned capex for repurposing Europe plant is estimated at $2 million to $3 million (Page 6).
- China plant repurposing investment is around Rs. 25 crores (~$3 million) (Page 6).
- MEHQ and Guaiacol production in Italy projected to start contributing commercially in FY26 after validation and stabilization in FY25 (Page 13).
- No new significant loans planned; some working capital may be needed for growth, but overall debt expected to remain stable with Rs. 25 crores of long-term loan repayment planned (Page 14-15).
- No further major write-offs or unaccounted losses expected; legacy issues accounted for (Page 14-15).
Track Camlin Fine — get its next earnings analysis in your feed
How does Camlin Fine rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Camlin Fine rank in Chemicals & Petrochemicals?
Compare Camlin Fine against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Camlin Fine's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…